What is Dyadic International's gross profit margin?

What were the key takeaways from Dyadic International's earnings call?

What is Dyadic International's latest dividend and current dividend yield?

What does Dyadic International do and what are its main business segments?

What factors drove the changes in Dyadic International's revenue and profit?

What guidance did Dyadic International's management provide for the next earnings period?

Did Dyadic International beat or miss consensus estimates last quarter?

What is the revenue and EPS growth rate for Dyadic International year over year?

- **Commercial Breakthrough**: First bulk sale of recombinant FGF in cultured meat market, signaling commercial viability.
- **CRISPR Advantage**: New gene editing capabilities accelerate product development and improve yields, positioning for competitive advantage.
- **Financial Resilience**: $10.4M cash balance supports growth, despite Q3 revenue decline driven by reduced collaboration activity.
- **Strategic Expansion**: Asian market partnership with Interlink targets high-growth regions, while biopharma collaborations secure $2.3M in non-dilutive funding.
- **Product Pipeline Momentum**: Multiple programs (albumin, transferrin, DNase I) in sampling/validation phases, with commercial launches expected in 2025-2026.

**【Management Opening Remarks】**
- Ping Lawson, CFO, welcomed participants and outlined the call structure, emphasizing forward-looking statements and risk factors.

**【President & COO Business Update】**
- **Commercial Milestone**: First bulk sale of recombinant bone morphogenetic protein (FGF) in the cultured meat market, marking a new chapter in commercialization.
- **CRISPR Partnership**: Acquired CRISPR-Cas9 gene editing capabilities via ERS Genomics license, enabling faster strain optimization and yield improvements.
- **Rebranding**: Transitioned to Dyadic Applied Biosolutions with a redesigned website, reflecting a shift to a product-focused strategy.
- **Product Pipeline**: Highlighted key programs including recombinant albumin (with ProLiant), transferrin (bovine/human), DNase I, and alpha-lactalbumin, with sampling and launch activities underway.
- **Market Expansion**: Partnered with Interlink to accelerate Asian market penetration, targeting Japan and South Korea for cell culture media and molecular biology reagents.

**【CEO Biopharma Program Update】**
- **Gates Foundation & CEPI Collaborations**: 
  - $2.3M received of $3M grant for malaria and RSV monoclonal antibody development; $2.4M potential funding for H5 influenza antigen production.
  - C1 platform demonstrated superior productivity vs. mammalian cell culture, with Phase I trial potential for H5 antigen.
- **EU Vaccine Hub Partnership**: Collaborating with FBS on EU-funded programs for filovirus vaccines and UVAX BioMirrors, validating C1’s scalability and cost-effectiveness.
- **NIAID Collaboration**: Generating process improvements for vaccine development, with broader platform applications.

**【CFO Financial Review】**
- **Revenue**: Q3 2025 revenue ($1.17M) down 40% YoY due to reduced R&D and license revenue, offset by $0.81M grant income (Gates/CEPI).
- **Costs**: 
  - COGS decreased 36% YoY to $0.26M, driven by lower production activity.
  - R&D expenses up 24% YoY to $0.57M due to internal product development.
  - G&A up 14% YoY to $1.48M, reflecting rebranding and business development costs.
- **Liquidity**: $10.4M cash as of Q3, including $4.9M from August 2025 stock offering.
- **Milestone Payments**: Received $0.5M from ProLiant (total $1.5M to date) and $0.25M from enzyme partner, with royalty potential.

**【Q&A Highlights】**
- **CRISPR Impact**: Enables faster strain optimization and higher yields, supporting commercial profitability without significant upfront costs.
- **Asian Market Strategy**: Interlink partnership targets bulk purchase orders from manufacturers, bypassing high-cost distribution networks.
- **Grant Endgame**: Biopharma programs provide non-dilutive funding and platform validation, with potential for future licensing opportunities.
- **Cash Burn**: Expect operating expenses to remain stable, with Q4 product revenue contributing to cash flow.


Dyadic International, Inc. (DYAI) Q3 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

DYAI

DYAI fundamentals

You can ask Aime